Cantor Fitzgerald reaffirmed their overweight rating on shares of Uniqure (NASDAQ:QURE) in a research note issued to investors on Monday, Briefing.com Automated Import reports. They currently have a $94.00 price objective on the biotechnology company’s stock, up from their previous price objective of $81.00. Cantor Fitzgerald also issued estimates for Uniqure’s FY2019 earnings at ($2.86) EPS and FY2020 earnings at ($3.24) EPS.
Several other research firms have also commented on QURE. SunTrust Banks upped their price target on shares of Everbridge to $87.00 and gave the company a buy rating in a research report on Tuesday, May 7th. Janney Montgomery Scott reaffirmed a buy rating on shares of Uniqure in a research report on Tuesday, June 11th. BidaskClub lowered shares of Xilinx from a buy rating to a hold rating in a research report on Saturday, June 15th. Zacks Investment Research raised shares of SCHNEIDER ELEC /ADR from a hold rating to a buy rating and set a $20.00 price target for the company in a research report on Friday, July 5th. Finally, Robert W. Baird began coverage on shares of Uniqure in a research report on Thursday, March 28th. They set an outperform rating and a $85.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $77.00.
Shares of NASDAQ:QURE opened at $68.65 on Monday. Uniqure has a fifty-two week low of $21.98 and a fifty-two week high of $82.49. The stock has a 50-day simple moving average of $71.72. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.38. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -29.34 and a beta of 1.05.
Uniqure (NASDAQ:QURE) last issued its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.03). Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. The business had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $2.00 million. As a group, sell-side analysts anticipate that Uniqure will post -3 EPS for the current year.
In related news, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $77.45, for a total value of $619,600.00. Following the completion of the sale, the chief executive officer now directly owns 409,407 shares of the company’s stock, valued at approximately $31,708,572.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christian Klemt sold 1,546 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total transaction of $88,400.28. Following the completion of the sale, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. Insiders sold a total of 23,546 shares of company stock valued at $1,556,820 over the last three months. 2.91% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Harvest Group Wealth Management LLC purchased a new stake in Uniqure in the 1st quarter worth approximately $26,000. Pearl River Capital LLC purchased a new stake in Uniqure in the 1st quarter worth approximately $32,000. Legal & General Group Plc increased its holdings in Uniqure by 264.2% in the 4th quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 700 shares in the last quarter. Financial Gravity Wealth Inc. purchased a new stake in Uniqure in the 1st quarter worth approximately $153,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in Uniqure in the 2nd quarter worth approximately $211,000. 60.10% of the stock is owned by institutional investors.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Read More: Can systematic risk be avoided?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.